PURPOSE: Increased plasma homocysteine levels have been found in patients with primary open angle glaucoma (POAG) and glaucoma secondary to pseudoexfoliation syndrome (PEXG). A common polymorphism of the methylenetetrahydrofolatereductase (MTHFR 677C>T) leads to moderately elevated plasma homocysteine levels particularly under conditions of impaired folate status. It was the aim of this study to investigate a hypothesized association between this polymorphism and the presence of either POAG or PEXG. METHODS: The present retrospective case-control study included a total of 553 participants comprising 204 patients with POAG, 138 patients with PEXG, and 211 control subjects. Genotyping for the MTHFR 677C>T polymorphism was performed by polymerase chain reaction (PCR). RESULTS: No significant difference in the genotype distribution of the MTHFR 677C>T polymorphism was found between control subjects and patients with POAG or PEXG. The prevalence of the MTHFR 677TT genotype was 6.9% in patients with POAG, 11.6% in patients with PEXG, and 9.5% in control subjects. CONCLUSIONS: The present data suggest that the MTHFR 677C>T polymorphism itself is not a major genetic risk factor for POAG and PEXG in a central European population.
PURPOSE: Increased plasma homocysteine levels have been found in patients with primary open angle glaucoma (POAG) and glaucoma secondary to pseudoexfoliation syndrome (PEXG). A common polymorphism of the methylenetetrahydrofolatereductase (MTHFR 677C>T) leads to moderately elevated plasma homocysteine levels particularly under conditions of impaired folate status. It was the aim of this study to investigate a hypothesized association between this polymorphism and the presence of either POAG or PEXG. METHODS: The present retrospective case-control study included a total of 553 participants comprising 204 patients with POAG, 138 patients with PEXG, and 211 control subjects. Genotyping for the MTHFR 677C>T polymorphism was performed by polymerase chain reaction (PCR). RESULTS: No significant difference in the genotype distribution of the MTHFR 677C>T polymorphism was found between control subjects and patients with POAG or PEXG. The prevalence of the MTHFR 677TT genotype was 6.9% in patients with POAG, 11.6% in patients with PEXG, and 9.5% in control subjects. CONCLUSIONS: The present data suggest that the MTHFR 677C>T polymorphism itself is not a major genetic risk factor for POAG and PEXG in a central European population.
Authors: J B Roedl; S Bleich; U Reulbach; N von Ahsen; U Schlötzer-Schrehardt; R Rejdak; G O H Naumann; F E Kruse; J Kornhuber; A G M Jünemann Journal: J Neural Transm (Vienna) Date: 2006-08-24 Impact factor: 3.575
Authors: Dimitrios Chiras; Konstantina Tzika; Haris Kokotas; Samantha C Oliveira; Maria Grigoriadou; Anastasia Kastania; Kleanthi Dima; Maria Stefaniotou; Miltiadis Aspiotis; Michael B Petersen; Christos Kroupis; George Kitsos Journal: Mol Vis Date: 2013-05-06 Impact factor: 2.367
Authors: Bao Jian Fan; Teresa Chen; Cynthia Grosskreutz; Louis Pasquale; Douglas Rhee; Elizabeth DelBono; Jonathan L Haines; Janey L Wiggs Journal: Mol Vis Date: 2008-12-26 Impact factor: 2.367